0001104659-24-026154.txt : 20240221
0001104659-24-026154.hdr.sgml : 20240221
20240221190042
ACCESSION NUMBER: 0001104659-24-026154
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240216
FILED AS OF DATE: 20240221
DATE AS OF CHANGE: 20240221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lee Jennifer Kayden
CENTRAL INDEX KEY: 0001801372
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38223
FILM NUMBER: 24661698
MAIL ADDRESS:
STREET 1: C/O KRYSTAL BIOTECH, INC.
STREET 2: 2100 WHARTON STREET, SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
FORMER NAME:
FORMER CONFORMED NAME: Chien Jennifer
DATE OF NAME CHANGE: 20200128
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001649904
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 462159271
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 857-264-4280
MAIL ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: RHYTHM METABOLIC, INC.
DATE OF NAME CHANGE: 20150803
4
1
tm246920-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-02-16
0
0001649904
RHYTHM PHARMACEUTICALS, INC.
RYTM
0001801372
Lee Jennifer Kayden
C/O RHYTHM PHARMACEUTICALS, INC.
222 BERKELEY STREET, 12TH FLOOR
BOSTON
MA
02116
0
1
0
0
EVP, Head of North America
0
Common Stock
2024-02-16
4
A
0
33750
0
A
40602
D
Restricted Stock Units
2024-02-16
4
A
0
22000
0
A
Common Stock
22000
22000
D
Stock Option (Right to Buy)
49.23
2024-02-16
4
A
0
67000
0
A
2034-02-15
Common Stock
67000
67000
D
The Issuer previously granted the Reporting Person an award of restricted stock units that vest based on the Issuer's satisfaction of certain performance objectives. On February 16, 2024, the Board determined that the performance condition had been satisfied.
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date.
The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
/s/ Hunter Smith, Attorney-in-Fact for Jennifer Kayden Lee
2024-02-21